P2Y2R and Cyst Growth in Polycystic Kidney Disease.


Journal

Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836

Informations de publication

Date de publication:
07 Jun 2024
Historique:
received: 24 11 2023
accepted: 30 05 2024
medline: 7 6 2024
pubmed: 7 6 2024
entrez: 7 6 2024
Statut: aheadofprint

Résumé

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by multiple bilateral kidney cysts which gradually enlarge, resulting in a decline in kidney function. Cyst growth is significantly driven by ATP-dependent chloride secretion mediated by the ion channel TMEM16A. This pathway is further augmented in advanced stages of the disease by hypoxia and activation of the hypoxia-inducible factor (HIF) 1α. The mechanisms by which ATP leads to activation of TMEM16A and how HIF-1α contributes to cyst growth in vivo have remained elusive. Mice with an inducible tubule-specific deletion of Pkd1 were compared to mice with an additional co-deletion of the purinergic receptor P2y2r. Furthermore, animals were challenged by pharmacological activation of HIF-1α and Pkd1-deficient mice were treated with suramin, an antagonist of purinergic signaling. In addition, expression of P2Y2R, TMEM16A and HIF-1α was analyzed in nephrectomy samples from 27 ADPKD patients. Genetic deletion of P2y2r significantly inhibited cyst growth in vivo. In addition, aggravation of the polycystic phenotype mediated by pharmacological activation of HIF-1α was reduced by deletion of P2y2r. Application of suramin in order to pharmacologically inhibit purinergic signaling also suppressed cyst enlargement in vivo. Analysis of kidney samples from 27 ADPKD patients revealed significant expression of P2Y2R at the luminal site of the cyst-lining epithelium. P2Y2R was significantly expressed in human and mouse polycystic kidneys. Deletion and antagonism of P2Y2R reduced cyst enlargement in an ADPKD mouse model.

Sections du résumé

BACKGROUND BACKGROUND
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by multiple bilateral kidney cysts which gradually enlarge, resulting in a decline in kidney function. Cyst growth is significantly driven by ATP-dependent chloride secretion mediated by the ion channel TMEM16A. This pathway is further augmented in advanced stages of the disease by hypoxia and activation of the hypoxia-inducible factor (HIF) 1α. The mechanisms by which ATP leads to activation of TMEM16A and how HIF-1α contributes to cyst growth in vivo have remained elusive.
METHODS METHODS
Mice with an inducible tubule-specific deletion of Pkd1 were compared to mice with an additional co-deletion of the purinergic receptor P2y2r. Furthermore, animals were challenged by pharmacological activation of HIF-1α and Pkd1-deficient mice were treated with suramin, an antagonist of purinergic signaling. In addition, expression of P2Y2R, TMEM16A and HIF-1α was analyzed in nephrectomy samples from 27 ADPKD patients.
RESULTS RESULTS
Genetic deletion of P2y2r significantly inhibited cyst growth in vivo. In addition, aggravation of the polycystic phenotype mediated by pharmacological activation of HIF-1α was reduced by deletion of P2y2r. Application of suramin in order to pharmacologically inhibit purinergic signaling also suppressed cyst enlargement in vivo. Analysis of kidney samples from 27 ADPKD patients revealed significant expression of P2Y2R at the luminal site of the cyst-lining epithelium.
CONCLUSIONS CONCLUSIONS
P2Y2R was significantly expressed in human and mouse polycystic kidneys. Deletion and antagonism of P2Y2R reduced cyst enlargement in an ADPKD mouse model.

Identifiants

pubmed: 38848134
doi: 10.1681/ASN.0000000000000416
pii: 00001751-990000000-00348
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : 509149993
Organisme : Deutsche Forschungsgemeinschaft
ID : 509149993

Informations de copyright

Copyright © 2024 by the American Society of Nephrology.

Auteurs

Andre Kraus (A)

Department of Nephrology and Hypertension, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and University Hospital, D-91054 Erlangen, Germany.

Kathrin Skoczynski (K)

Department of Nephrology and Hypertension, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and University Hospital, D-91054 Erlangen, Germany.

Martin Brötsch (M)

Department of Chemistry and Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), D-91054 Erlangen, Germany.

Nicolai Burzlaff (N)

Department of Chemistry and Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), D-91054 Erlangen, Germany.

Jens Leipziger (J)

Department of Biomedicine, Physiology, Aarhus University, 8000, Aarhus, Denmark.

Mario Schiffer (M)

Department of Nephrology and Hypertension, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and University Hospital, D-91054 Erlangen, Germany.

Maike Büttner-Herold (M)

Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and University Hospital, D-91054 Erlangen, Germany.

Bjoern Buchholz (B)

Department of Nephrology and Hypertension, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and University Hospital, D-91054 Erlangen, Germany.

Classifications MeSH